Download - Treatment Planning I Isodose Distributions
![Page 1: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/1.jpg)
ISODOSE DISTRIBUTIONS
• Isodose Chart• Measurements of isodose curves• Parameters of isodose curves
– Beam quality– Source size, SSD and SDD – the penumbra
effect– Collimation and flattening filter– Field size– Wedge Filters
![Page 2: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/2.jpg)
ISODOSE DISTRIBUTIONS
• Combination of radiation fields– Parallel opposed fields– Multiple fields
• Isocentric techniques– Stationary beams– Rotation therapy
• Wedge Fields Techniques• Tumor dose specification
![Page 3: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/3.jpg)
Isodose Chart
SSD SAD
![Page 4: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/4.jpg)
Isodose Chart
![Page 5: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/5.jpg)
Isodose Chart
![Page 6: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/6.jpg)
Measurements of isodose curves
• 3D water phantoms
![Page 7: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/7.jpg)
Parameters of isodose curves
200 kvp 60Co
4 MV 10 MV
![Page 8: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/8.jpg)
![Page 9: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/9.jpg)
Parameters of isodose curves
• Source SizeS
SDD
SSD
dP
A B
C
D E
Homework: Derive the penumbra (DE) as a function of other parameters
![Page 10: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/10.jpg)
Parameters of isodose curves
• Flattening Filter• Flatness defined at 10
cm depth• Horns at dmax• Below 10 cm,
rounding off of the profiles
• Energy off axis is lower than central axis
![Page 11: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/11.jpg)
Parameters of isodose curves
• Field size– SSD technique: the field size is defined at the
surface– SAD technique: the field size is defined at the
depth– Field size defined as the 50% line, normalized
to the central axis value at the depth.
![Page 12: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/12.jpg)
Wedge FiltersNormalized at dmax A: with wedge B: without wedge
![Page 13: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/13.jpg)
Wedge Filters
![Page 14: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/14.jpg)
Wedge Angle
• Refers to the complement of the angle the isodose line is tilted in relation to the central axis, for a given depth.
• This depth is normally defined as 10 cm (ICRU 24).
![Page 15: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/15.jpg)
θ
![Page 16: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/16.jpg)
Wedge Transmission Factor• Measured at some depth beyond the dmax, usually 10
cm.• Old 60Co isodose curves were normalized to the dmax
without the wedge. The isodose curves already included the wedge factor.
• With advent of TPS, we normally input the isodosecurves normalized to the dmax with the wedge, and introduce a wedge factor to account for the transmission factor of the wedge.
• Wedge factor depends on the depth and field size.
![Page 17: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/17.jpg)
Wedge Systems
• Wedge for selected field sizes, were used for 60Co units because of limited output of the units.
![Page 18: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/18.jpg)
Design of Wedge Filters
![Page 19: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/19.jpg)
Universal Wedges• Elekta provide this technique in their linacs.• It is a 60 wedge which is mounted in a carrousel
that goes in and out of the photon beam.• If you need a different wedge angle, the linac
automatically weight treatment to provide for the angle needed (e.g., 30 wedge is done by assigning 50% of the treatment with an open beam and 50% of the treatment with the 60 wedge)
![Page 20: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/20.jpg)
Dynamic or Virtual Wedges
• To be discussed separately
![Page 21: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/21.jpg)
Combination of Radiation Fields
Different weights
![Page 22: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/22.jpg)
Parallel Opposed Fields
![Page 23: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/23.jpg)
![Page 24: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/24.jpg)
![Page 25: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/25.jpg)
![Page 26: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/26.jpg)
![Page 27: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/27.jpg)
Multiple Fields
N -> ∞ = Rotation Therapy
![Page 28: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/28.jpg)
![Page 29: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/29.jpg)
Stationary Beams
![Page 30: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/30.jpg)
![Page 31: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/31.jpg)
![Page 32: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/32.jpg)
![Page 33: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/33.jpg)
![Page 34: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/34.jpg)
![Page 35: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/35.jpg)
Rotation Therapy
100 degrees
180 degrees
360 degrees
4 MVField Size = 7x12 cm
![Page 36: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/36.jpg)
Wedge Fields Technique
90 / 2oθ φ= −
![Page 37: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/37.jpg)
Wedge Fields Technique
![Page 38: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/38.jpg)
![Page 39: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/39.jpg)
ICRU 50 AND 62
![Page 40: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/40.jpg)
Treatment Planning ProcessTreatment Planning Process
•Gross Tumor Volume (GTV)palpable or imaged
•Clinical Target Volume (CTV)GTV + subclinicalmultiple CTV’s possible
•Planning Target Volume (PTV)CTV + margin (internal+setup)
![Page 41: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/41.jpg)
Treatment Planning ProcessTreatment Planning Process
•Gross Tumor Volume (GTV)GTV is the gross demonstrable extent andlocation of the malignant growthThe GTV consists of primary tumor (GTVPrimary) and possibly metastatic lympha-denopathy (GTV nodal) or other metastases(GTV M).
![Page 42: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/42.jpg)
Treatment Planning ProcessTreatment Planning Process
•Clinical Target Volume (CTV)CTV is a tissue volume that contains demons-trable GTV and/or subclinical malignantdiseases that must be eliminated. This volumehas to be treated adequately in order to achievethe aim of radical therapy.
![Page 43: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/43.jpg)
Treatment Planning ProcessTreatment Planning Process
•Clinical Target Volume (CTV)•Description of treatment of subclinical
extension adjacent to a GTVClinical experience indicates that outside theGTV there is generally subclinical involve-ment that can not be detected by the stagingprocedures. This CTV is then usually denotedby CTV 1.
![Page 44: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/44.jpg)
Treatment Planning ProcessTreatment Planning Process
•Clinical Target Volume (CTV)•Description of treatment of subclinical
extension at a distance from a GTVAdditional volumes (CTV’s) with presumedsubclinical spread (e.g. Regional lymph nodes)may be considered for therapy. They are thendesignated by CTV II, CTV III, etc.
![Page 45: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/45.jpg)
Treatment Planning ProcessTreatment Planning Process
•Internal Target Volume (CTV)•ICRU 62 recommends that an internal margin(IM) be added to CTV to account for internalphysiological movements and variation in size,shape, and position of the CTV during therapyin relation to na internal reference point and itscorresponding coordinate system.
![Page 46: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/46.jpg)
Treatment Planning ProcessTreatment Planning Process
•Planning Target Volume (PTV)The volume that includes CTV with an IMAs well as a set-up margin (SM) for patientMovement and set-up uncertainties is calledThe planning target volume (PTV). To Delineate PTV, IM and SM are not addedLinearly but are combined subjectively.
![Page 47: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/47.jpg)
Treatment Planning ProcessTreatment Planning Process
GTVGTVCTVCTV
PTVPTV
![Page 48: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/48.jpg)
TreatmentTreatment IncludedIncluded
GTVGTVCTVCTV
PTVPTVIrradiatedVolume
TreatedVolume
![Page 49: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/49.jpg)
Treatment Planning ProcessTreatment Planning Process
•Planning Organ at Risk Volume (PRV)The organ at risk (OR) needs adequate protectionjust as CTV needs adequate treatments.Once the OR is identified, margins need to beadded to account for its movements, internalas well as set-up.
![Page 50: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/50.jpg)
Treatment Planning ProcessTreatment Planning Process
• Treated VolumeAdditional margins must be provided around thetarget volume to allow for limitations of thetreatment technique. Thus the minimum targetdose should be represented by an isodose surfacewhich adequately covers the PTV to providethat margin. The volume enclosed by this isodosesurface is called the treated volume.
![Page 51: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/51.jpg)
Treatment Planning ProcessTreatment Planning Process
• Irradiated VolumeThe volume of tissue receiving a significant dose (e.g., >= 50% of the specified target dose) is calledthe irradiated volume.
![Page 52: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/52.jpg)
Specifications of Target Dose
Maximum target dose
(larger than 2 cm2)
Minimum target dose
![Page 53: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/53.jpg)
ICRU Volumes and Margins
![Page 54: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/54.jpg)
Specification of Target Dose
• The ICRU Reference Point– The point should be selected so that the dose at this
point is clinically relevant and representative of thedose throughout the PTV
– The point should be easy to define in a clear andunambiguous way
– The point should be selected where the dose can beaccurately calculated
– The point should not lie in the penumbra region orwhere there is a steep dose gradient
![Page 55: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/55.jpg)
Specification of Target Dose
• Stationary Photon Beams– For single beam, the TD should be specified in the central
axis of the beam placed within the PTV– For parallel opposed, equally weighted beams, the point of
TD specification should be on the central axis midwaybetween the beam entrances
– For parallel opposed, unequally weigthed beams, the TD should be specified in the central axis placed within thePTV
– For any other arrangement of two or more intersecting beams, the point of TD specification should be at the intersection of the central axes of the beams placed within the PTV
![Page 56: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/56.jpg)
Specification of Target Dose
• Rotation Therapy– For full rotation or arcs of at least 270 degrees, the TD
should be specified at the center of the rotation in theprincipal plane.
– For smaller arcs, the TD should be stated in the principal plane, first at the center of rotation and, second, at thecenter of the target volume. This dual point specification is required because in small arc therapy, past pointtechniques are used that give maximum absorbed dose close to the center of the target area.
![Page 57: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/57.jpg)
Specification of Target Dose
• Additional Information– The specification of TD is only meaningful if sufficient
information is provided regarding the irradiation technique.– Radiation quality, SSD or SAD, field sizes, beam
modification devices, beam weighting, correction for inhomogeneities, dose fractionation and patient positioningshould be included as well.
![Page 58: Treatment Planning I Isodose Distributions](https://reader033.vdocument.in/reader033/viewer/2022051108/544bb19faf7959b0438b550f/html5/thumbnails/58.jpg)
Lab - 6 MV photon beam• Output in air (Sc)
– Field sizes at 100 cm 4,6,8,10,12,14,17,20,25,30,40– Distance to chamber = 100 cm– Copper buildup cap
• Output in phantom (Sc,p)– Field sizes at 100 cm 4,6,8,10,12,14,17,20,25,30,40– Distance to chamber = 100 cm– At dmax depth (1.5 cm)
• PDD for a 10x10 cm 100cm SSD– At dmax, 5, 10 and 15 cm depth
• TAR for a 10x10 cm– At dmax, 5, 10 and 15 cm depth